Karen Kelly - Concepedia

Author

Karen Kelly

University of California, Davis ORCID

Also Known As

K Kelly, K L Kelly, K S Karen, K. KELLY, K. Kelly, K. L. Kelly, K.W. Kelly, Karen Kelly, Karen L Kelly, Karen L. Kelly

693

Publications

21.2K

Citations

H-Index

206

Concepts

All Affiliations

University of California, Davis UC Davis Comprehensive Cancer Center The University of Texas MD Anderson Cancer Center University of Colorado Denver Fred Hutch Cancer Center

About

Karen Kelly is an author at University of California, Davis specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	111	5.8K
2	Health Sciences	22	34	1.9K
3	Education	5	5	85
4	Engineering	4	4	125
5	Language Studies	2	2	30

Karen Kelly

213

Publications

17.9K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer Mark G. Kris, Ronald B. Natale, Roy S. Herbst, JAMA	2003	2.5K
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial Karen Kelly, John Crowley, Paul A. Bunn, Journal of Clinical Oncology	2001	1.1K
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade Ziming Wang, Ethan G. Aguilar, Jesus I. Luna, Nature Medicine ObesityCancer ImmunosurveillancePd-1 Checkpoint BlockadeT Cell FunctionMedicine	2018	806
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study Andrea B. Apolo, Jeffrey R. Infante, Ani Sarkis Balmanoukian, Journal of Clinical Oncology	2017	580
Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023 Karen Kelly, Kari Chansky, Laurie E. Gaspar, Journal of Clinical Oncology	2008	568
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. Agnieszka Woźniak, John J. Crowley, S P Balcerzak, Journal of Clinical Oncology	1998	566
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial Karen Kelly, Nasser K. Altorki, Wilfried Eberhardt, Journal of Clinical Oncology	2015	477
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Apar Kishor Ganti, Billy W. Loo, M. Bassetti, Journal of the National Comprehensive Cancer Network	2021	431
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Mary L. Disis, Matthew H. Taylor, Karen Kelly, JAMA Oncology	2019	417
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study Allen M. Chen, Carol Felix, Pin‐Chieh Wang, The Lancet Oncology Cancer-associated VirusRadiation TherapyMedicineNasopharyngeal CancerReduced-dose Radiotherapy	2017	318

Page 1